Literature DB >> 1311304

Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor.

L A Tartaglia1, D V Goeddel.   

Abstract

To investigate the signaling mechanism of the 55-kDa tumor necrosis factor (TNF) receptor a functional transfection based assay was developed. The human 55-kDa TNF receptor, stably expressed in mouse L929 cells, was demonstrated to be activated specifically by agonist antibodies and to initiate a signal for cellular cytotoxicity. A deletion mutant of the human TNF receptor lacking most of the cytoplasmic domain was found to be completely defective in generating the signal for cytotoxicity. Additionally, expression of the truncated receptor substantially suppressed signaling by endogenous mouse TNF receptors in response to TNF, but not in response to specific anti-murine TNF receptor antibodies. These results suggest that aggregation of 55-kDa TNF receptor intracellular domains, which are not associated in the absence of ligand, is an important component of the signal for cellular toxicity. This work also provides an example of a dominant negative mutation in a transmembrane receptor that lacks a tyrosine kinase domain, and suggests a more general utility of dominant negative mutations in the investigation of cytokine receptor function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311304

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  Localization of the gD-binding region of the human herpes simplex virus receptor, HveA.

Authors:  J C Whitbeck; S A Connolly; S H Willis; W Hou; C Krummenacher; M Ponce de Leon; H Lou; I Baribaud; R J Eisenberg; G H Cohen
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 3.  Cytokine receptors: structure and signal transduction.

Authors:  B M Foxwell; K Barrett; M Feldmann
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 4.  Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms.

Authors:  C Trautwein; K Böker; M P Manns
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

5.  Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition.

Authors:  M Schreiber; L Sedger; G McFadden
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1-independent fashion in mouse macrophages.

Authors:  B W Winston; C A Lange-Carter; A M Gardner; G L Johnson; D W Riches
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Signal transduction by tumor necrosis factor mediated by JNK protein kinases.

Authors:  H K Sluss; T Barrett; B Dérijard; R J Davis
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.

Authors:  B S Sylla; S C Hung; D M Davidson; E Hatzivassiliou; N L Malinin; D Wallach; T D Gilmore; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 9.  The TNF receptor superfamily: role in immune inflammation and bone formation.

Authors:  Xin Cheng; Masa Kinosaki; Ramachandran Murali; Mark I Greene
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 10.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.